BioCentury
ARTICLE | Clinical News

Boehringer's Stiolto Respimat misses in Phase III for COPD

May 11, 2018 6:25 PM UTC

In March, Boehringer Ingelheim GmbH (Ingelheim, Germany) reported data from the Phase III DYNAGITO trial in 7,880 patients with chronic obstructive pulmonary disease (COPD) showing that Stiolto Respimat tiotropium/olodaterol (Inspiolto Respimat, Spiolto Respimat) missed the primary endpoint of decreasing the rate of moderate to severe COPD exacerbations vs. Spiriva Respimat tiotropium bromide. Stiolto Respimat non-significantly decreased the rate by 7% vs. Spiriva Respimat (p=0.0498). The predefined threshold for significance was a p-value of ≤0.01. Data were published in The Lancet Respiratory Medicine.

Patients in the double-blind, international trial received once-daily 5 μg/5 μg tiotropium/olodaterol or 5 μg tiotropium for 52 weeks...